Buy or sell guide

A fast read on Wall Street conviction, live analyst commentary on X, and current valuation context for Thermo Fisher Scientific Inc..
Updated 2026-06-21
Wall Street currently rates TMO buy with a 12-month price target of $600 (+29.1% upside). The sections below cover the bull case, key risks, and latest earnings context for TMO.
Wall Street verdict
42 analysts currently cover TMO. Below is their consensus rating, price target range, and implied upside.
According to 42 analysts, Thermo Fisher Scientific Inc. (TMO) is rated Buy with a consensus 12-month price target of $600 — representing 29% upside from today's price of $465. The bull case target is $683, the bear case is $490.
At $464.61, the consensus setup implies +29.1% versus the 12-month target.
Below, compare that institutional answer with the live analyst commentary on X for TMO right now.
Analyst ratings update weekly. Get TMO's next verdict in your inbox.
Free. No account needed. Unsubscribe any time.
Live commentary on X
Real posts from high-reach stock analysts mentioning TMO, shown exactly as written. Sorted by engagement — most discussed first.
No recent posts captured
No high-reach analysts have posted about TMO in the last 7 days. Check back after the next earnings release or market-moving event.
Should you buy TMO?
A structured look at the bull case, the risks, and the most recent earnings execution for TMO before you decide whether to buy, hold, or sell.
TMO beat estimates last quarter. Below are the key reasons analysts remain constructive and the risks that could change that view.
What keeps the long thesis intact
Wall Street rates TMO buy, giving the bull case institutional backing from 42 analysts.
What can break the setup quickly
Watch whether new negative commentary on TMO points to these structural risks or is simply reacting to short-term price moves.
Last Quarter
Deep dive into TMO consensus models and risk factors.
Wall Street verdict, signals, and target summaries.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TMO stock.
TMO looks attractive at current levels — Wall Street's consensus rating is "Buy" with a $600 price target (+29.1% upside from $464.61). This is informational only — verify the data and consider your own risk tolerance before deciding.
Timing depends on your horizon, but the data signals are: consensus rating "Buy" with +29.1% upside to the $600 target. Recent activity is mixed — 1 analysts raised and 1 cut targets in the past 30 days.
TMO's consensus 12-month price target is $600, set by 42 Wall Street analysts. The bull case high is $683 and the bear case low is $490. From the current price of $464.61, this implies +29.1% upside.
TMO appears undervalued — the $600 consensus target is +29.1% above today's $464.61. It trades at a forward P/E of 18.7x. Targets range from $490 (bear) to $683 (bull), reflecting different assumptions about growth and margins.
TMO reports next quarter. Earnings-week moves are volatile — historically, analyst targets revise upward after a beat and downward after a miss. The current consensus is "Buy" with a $600 target. Consider position sizing rather than going all-in pre-print.
Of 42 analysts covering Thermo Fisher Scientific Inc. (TMO): 0 Strong Buy, 37 Buy, 5 Hold, 0 Sell, 0 Strong Sell — a "Buy" consensus. The 12-month price target is $600 (range $490–$683). Bullish analysts outnumber bearish by more than 2-to-1.
No analyst currently rates TMO a Sell, but the 5 Hold ratings reflect concerns about valuation, execution risk, or near-term catalysts. See the Bull vs. Risk cards above for the specific theses on Thermo Fisher Scientific Inc..
This page is for informational purposes only and does not constitute financial advice. Always conduct your own research before investing.